Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma
Journal of Clinical Laboratory Analysis · 2026
DOI: 10.1002/jcla.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2026. Verfasst von Lelang Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Biomarkers, Tumor, Proteomics, Pancreatic Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Sichuan Province, Health Commission of Sichuan Province, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that is often diagnosed after curative treatment is no longer feasible. Existing biomarkers, particularly CA19‐9, have limited sensitivity and specificity. Plasma proteins that capture tumor‐associated biological alterations may therefore provide useful signals for earlier detection.
Methods
Plasma samples from 99 patients with PDAC and 30 healthy controls were analyzed using data‐independent acquisition (DIA) proteomics. Differentially expressed proteins were identified using predefined statistical thresholds and further examined by functional enrichment analysis. Selected candidate biomarkers were validated by ELISA in an independent subset.
Results
Among 565 quantified plasma proteins, 52 were differentially expressed between PDAC and controls. These proteins were enriched in extracellular processes, cholesterol metabolism, complement and coagulation cascades, and pancreatic secretion pathways. ELISA validation confirmed higher plasma levels of Cathepsin S, CTRB2, MARCO, PIGR, PRDX6, REG1A, Trypsin‐2, and PEP‐FAP in patients with PDAC compared with healthy controls. ROC analyses showed moderate‐to‐good discriminatory performance for several candidates, and the MARCO + PEP‐FAP model improved classification compared with either marker alone.
Conclusion
These findings reveal circulating proteins linked to key PDAC‐related biological processes and identify eight candidates for further evaluation in multi‐protein diagnostic panels. Larger validation studies incorporating clinically relevant disease control groups are warranted to determine their diagnostic specificity and clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Pancreatic Surgery and Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Yong Zhang, Ang Li
Förderung
- Department of Science and Technology of Sichuan Province
- Health Commission of Sichuan Province
- West China Hospital, Sichuan University
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Science and Technology Department of Sichuan Province
Zitieren
APA
Xiang, L., Jin, Y., Hu, R., He, Y., Zhang, Y., & Li, A. (2026). Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70313
Vancouver
Xiang L, Jin Y, Hu R, He Y, Zhang Y, Li A. Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70313
BibTeX
@article{Xiang2026,
author = {Xiang, Lelang and Jin, Yi and Hu, Ran and He, Yuhang and Zhang, Yong and Li, Ang},
title = {Plasma Proteomic Profiling Identifies Candidate Biomarkers for Pancreatic Ductal Adenocarcinoma},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
doi = {10.1002/jcla.70313}
}
EUVIMED